Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02443324
Title A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC or Transitional Cell Carcinoma of the Urothelium
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications
Therapies
Age Groups: adult
Covered Countries USA | GBR | FRA | ESP | DEU


No variant requirements are available.